Edition:
United Kingdom

Cipla Ltd (CIPL.NS)

CIPL.NS on National Stock Exchange of India

596.20INR
6:13am GMT
Change (% chg)

Rs-4.20 (-0.70%)
Prev Close
Rs600.40
Open
Rs603.45
Day's High
Rs604.20
Day's Low
Rs592.00
Volume
398,789
Avg. Vol
1,513,189
52-wk High
Rs663.40
52-wk Low
Rs480.20

Chart for

About

Cipla Limited is a holding company. The Company is a pharmaceutical company. The Company's strategic business units include Active Pharmaceutical Ingredients (APIs), Respiratory and Cipla Global Access. The Company's geographical segments include India, USA, South Africa and Rest of the World. The Company manufactures metered... (more)

Overall

Beta: 0.47
Market Cap(Mil.): Rs471,067.19
Shares Outstanding(Mil.): 804.69
Dividend: 2.00
Yield (%): 0.34

Financials

  Industry Sector
P/E (TTM): -- 31.10 16.64
EPS (TTM): -- -- --
ROI: -- 14.90 10.66
ROE: -- 16.41 14.30

Indian shares gain over 1 pct after 7 days of falls

Feb 8 Indian shares rose more than 1 percent on Thursday after seven consecutive sessions of declines, as market heavyweights such as Infosys recovered and as drug maker Cipla gained on solid earnings.

08 Feb 2018

UPDATE 1-India's Cipla Q3 profit rises, but below estimates

Feb 7 Cipla Ltd, India's fourth-largest drugmaker by revenue, said third-quarter net profit rose 7 percent on strong domestic sales, but fell short of analysts' estimates.

07 Feb 2018

BRIEF-Cipla Says Key Performance Metrics Inline With Co's Internal Targets

* SAYS KEY PERFORMANCE METRICS LOOK HEALTHY AND ARE INLINE WITH CO'S INTERNAL TARGETS Source text - http://bit.ly/2BhN3M6 Further company coverage:

07 Feb 2018

India's Cipla Q3 profit rises about 7 pct

Feb 7 Cipla Ltd, India's fourth-largest drugmaker by revenue, posted an about 7 percent rise in third-quarter net profit on Wednesday, but missed analysts' estimates.

07 Feb 2018

BRIEF-India's Cipla Dec-Qtr Consol Profit Up 7 Pct

* DEC QUARTER CONSOL NET PROFIT 4.01 BILLION RUPEES VERSUS PROFIT OF 3.75 BILLION RUPEES LAST YEAR

07 Feb 2018

BRIEF-India's Cipla Gets U.S. FDA Nod For Generic Viread Tablets

* GETS ANDA FOR TENOFOVIR DISOPROXIL FUMARATE TABLETS FROM U.S. FDA Source text - http://bit.ly/2DW6lbS Further company coverage:

29 Jan 2018

BRIEF-Kiadis Pharma Proposes Subhanu Saxena, Former Cipla CEO, As New Supervisory Board Member

* KIADIS PHARMA PROPOSES FORMER CIPLA CEO SUBHANU SAXENA AS NEW SUPERVISORY BOARD MEMBER

16 Jan 2018

BRIEF-Cipla Launches Q-Tib Globally

* SAYS GOT APPROVAL FOR PRODUCT Q-TIB FROM WORLD HEALTH ORGANISATION

30 Nov 2017

BRIEF-Cipla gets final approval for generic Dacogen​

* Drug indicated for treatment of patients with myelodysplastic syndromes

20 Nov 2017

Yes Bank, IndusInd to join India's BSE Sensex index; Lupin, Cipla dropped

Nov 17 Indian private sector lenders Yes Bank Ltd and IndusInd Bank Ltd will join the BSE stock exchange's 30-member Sensex index, effective Dec. 18, the index provider said on Friday.

17 Nov 2017

Earnings vs. Estimates